- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03066258
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
May 12, 2023 updated by: REGENXBIO Inc.
A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD).
VEGF inhibitors (anti-VEGF), including ranibizumab (LUCENTIS®, Genentech) and aflibercept (EYLEA®, Regeneron), have been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision.
However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients.
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein.
The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit:risk profile.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This Phase I/IIa, open-label, multiple-cohort, dose-escalation study was designed to evaluate the safety and tolerability of RGX-314 gene therapy in subjects with previously treated nAMD.
Five doses were studied in approximately 42 subjects.
Subjects who met the inclusion/exclusion criteria and had an anatomic response to an initial anti-VEGF injection received a single dose of RGX-314 administered by subretinal delivery.
RGX-314 uses an AAV8 vector that contains a gene that encodes for a monoclonal antibody fragment which binds to and neutralizes VEGF activity.
Safety was the primary focus for the initial 24 weeks after RGX-314 administration (primary study period).
Following completion of the primary study period, subjects continued to be assessed until 104 weeks following treatment with RGX-314.
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93103
- Santa Barbara Location
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Baltimore Location
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Boston Location
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Reno Location
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Philadelphia location 1
-
Philadelphia, Pennsylvania, United States, 19107
- Philadelphia location 2
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Memphis location
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston location
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 87 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients ≥ 50 and ≤ 89 years with a diagnosis of subfoveal CNV (Choroidal neovascularization) secondary to AMD in the study eye receiving prior intravitreal anti-VEGF therapy.
- BCVA (Best Corrected Visual Acuity) between ≤20/63 and ≥20/400 (≤63 and ≥19 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) for the first patient in each cohort followed by BCVA between ≤20/40 and ≥20/400 (≤73 and ≥19 ETDRS letters) for the rest of the cohort.
- History of need for and response to anti-VEGF therapy.
- Response to anti-VEGF at trial entry (assessed by SD-OCT (Spectral Domain Optical Coherence Tomography) at week 1)
- Must be pseudophakic (status post cataract surgery) in the study eye.
- AST (Aspartate aminotransferase)/ALT (Alanine aminotransferase) < 2.5 × ULN (Upper limit of normal); TB (Total bilirubin) < 1.5 × ULN; PT (Prothrombin time) < 1.5 × ULN; Hb > 10 g/dL (males) and > 9 g/dL (females); Platelets > 100 × 10^3/µL; eGFR (Estimated glomerular filtration rate) > 30 mL/min/1.73 m^2
- Must be willing and able to provide written, signed informed consent.
Exclusion Criteria:
- CNV or macular edema in the study eye secondary to any causes other than AMD.
- Any condition preventing visual acuity improvement in the study eye, eg, fibrosis, atrophy, or retinal epithelial tear in the center of the fovea.
- Active or history of retinal detachment in the study eye.
- Advanced glaucoma in the study eye.
- History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational product, other than anti-VEGF therapy, in the 6 months prior to screening.
- Presence of an implant in the study eye at screening (excluding intraocular lens).
- Myocardial infarction, cerebrovascular accident, or transient ischemic attacks within the past 6 months.
- Uncontrolled hypertension (systolic blood pressure [BP] >180 mmHg, diastolic BP >100 mmHg) despite maximal medical treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
3E9 GC (genome copies)/eye of RGX-314 (E means the exponential constant)
|
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
|
Experimental: Cohort 2
1E10 GC/eye of RGX-314
|
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
|
Experimental: Cohort 3
6E10 GC/eye of RGX-314
|
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
|
Experimental: Cohort 4
1.6E11 GC/eye of RGX-314
|
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
|
Experimental: Cohort 5
2.5E11 GC/eye of RGX-314
|
RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))
Time Frame: 26 weeks (24 weeks following RGX-314 administration)
|
Participants with ocular and non-ocular AEs and SAEs through 26 weeks (24 weeks following RGX-314 administration)
|
26 weeks (24 weeks following RGX-314 administration)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (Participants With Ocular and Non-ocular AEs and SAEs)
Time Frame: 106 weeks (104 weeks following RGX-314 administration)
|
Participants with ocular and non-ocular AEs and SAEs
|
106 weeks (104 weeks following RGX-314 administration)
|
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Time Frame: 106 weeks (104 weeks following RGX-314 administration)
|
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score.
A higher score represents better vision.
|
106 weeks (104 weeks following RGX-314 administration)
|
Change From Baseline in CRT (Central Retinal Thickness)
Time Frame: 106 weeks (104 weeks following RGX-314 administration)
|
Retinal fluid status of the study eye was evaluated using spectral domain OCT (Optical Coherence Tomography).
A decrease in value indicates a decrease in fluid
|
106 weeks (104 weeks following RGX-314 administration)
|
Supplemental Injections (Annualized Rate of Supplemental Injections)
Time Frame: 106 weeks (104 weeks following RGX-314 administration)
|
The number of supplemental anti-VEGF injections given after RGX-314 was administered.
Injections per year which were determined by the number of supplemental injections divided total follow-up in study days which is annualized to a per year rate.
Injections were given for signs of worsening disease at a study visit, per the discretion of the investigator.
|
106 weeks (104 weeks following RGX-314 administration)
|
Mean Change From Baseline in Area of CNV (Choroidal Neovascularization)
Time Frame: 106 weeks (104 weeks following RGX-314 administration)
|
Area of Choroidal Neovascularization of the study eye was assessed with color fundus photography.
Analysis was performed by the central reading center.
An increase in value represents an increase in CNV.
|
106 weeks (104 weeks following RGX-314 administration)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffrey Heier, MD, Ophthalmic Consultants of Boston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 29, 2017
Primary Completion (Actual)
November 24, 2019
Study Completion (Actual)
June 17, 2021
Study Registration Dates
First Submitted
February 17, 2017
First Submitted That Met QC Criteria
February 22, 2017
First Posted (Actual)
February 28, 2017
Study Record Updates
Last Update Posted (Actual)
May 16, 2023
Last Update Submitted That Met QC Criteria
May 12, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RGX-314-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on RGX-314
-
AbbVieCompletedWet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
AbbVieAbbVieRecruiting
-
AbbVieAbbVieEnrolling by invitationWet Macular Degeneration | Neovascular Age-related Macular DegenerationUnited States
-
AbbVieAbbVieRecruitingNeovascular Age-Related Macular Degeneration (nAMD)United States
-
AbbVieRecruitingCNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMDUnited States, Puerto Rico, Canada
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Canada
-
Sunesis PharmaceuticalsCompletedAdvanced Solid TumorsUnited States
-
AbbVieRecruitingCNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMDUnited States
-
ImmPACT BioRecruitingRefractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Brazil